From Nvidia: 2024-11-18 13:30:00

Global pharmaceutical and techbio industry leaders, academic pioneers, and AI researchers are adopting the open-source NVIDIA BioNeMo Framework to advance drug discovery and accelerate molecule design. The framework offers accelerated computing tools for biomolecular research and is supported by organizations like Argonne National Laboratory and Genentech. Additionally, NVIDIA has introduced the BioNeMo Platform to accelerate AI model creation and deployment for drug discovery. The platform includes optimized NIM microservices for secure and scalable AI inference, as well as BioNeMo Blueprints for wet-lab and computational workflows. The platform also supports industry-leading models like AlphaFold2, DiffDock 2.0, RFdiffusion, and ProteinMPNN to speed up the process of designing novel proteins and predicting protein structures. BioNeMo now includes new acceleration libraries, such as cuEquivariance, to accelerate mathematical computations essential for chemistry predictions. Companies can use BioNeMo Blueprints to scale their AI deployments and customize reference AI workflows for enterprise-grade production pipelines. Over 200 techbios, large pharma, and startup users are integrating BioNeMo into their drug discovery platforms, with global system integrators and cloud service providers like Accenture and AWS bringing BioNeMo Blueprints to enterprises worldwide.



Read more at Nvidia: NVIDIA Opens BioNeMo to Scale Digital Biology for Global Biopharma and Scientific Industry